findmyKOL
Clinical trialNCT00294866CompletedPhase 4Interventional

Effect of Paricalcitol on Markers of Inflammation in Hemodialysis Patients

SponsorFresenius Medical Care North AmericaEnrollment64Kidney Failure
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Studies have shown that patients with ESRD on hemodialysis have high levels of inflammatory markers which may contribute to the high rates of cardiovascular disease and mortality seen in these patients. Vitamin D use in dialysis patients has been shown to have a survival benefit, with paricalcitol at advantage over calcitriol. Since there is some evidence for involvement of the vitamin D receptor in inflammation, this study is designed to look for an effect of paricalcitol on markers of inflammation in hemodialysis patients.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Southwest Nephrology

    Evergreen Park, Illinois, United States

  • Nephrology Center

    Kalamazoo, Michigan, United States

  • Nephrology Associates P.A.

    West Orange, New Jersey, United States

  • Delaware Valley Nephrology

    Philadelphia, Pennsylvania, United States

  • Nephrology Associates, Pc

    Nashville, Tennessee, United States

  • Tyler Nephrology Associates

    Tyler, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Paricalcitol →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Mar 2006
Primary completion
31 Jan 2008
Completion
31 Jan 2008
Last update posted
8 Apr 2010
Registered enrollment
64
Registry id
NCT00294866
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.